ARTICLE | Clinical News
Apricus Biosciences preclinical data
October 4, 2010 7:00 AM UTC
In rodents, rectal delivery of rituximab formulated with Apricus' NexACT delivery technology achieved similar blood levels of the chimeric mAb against CD20 antigen as compared to subcutaneous administration. ...